Y Mabs Therapeutics Inc Revenue Growth Rates (YMAB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Y mabs Therapeutics inc   (NASDAQ: YMAB)
 

YMAB's Revenue Growth by Quarter and Year

Y Mabs Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

YMAB Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June 18.86
1st Quarter March 20.90
FY 39.76

YMABs Annual Revenue
Y Mabs Therapeutics Inc 's Revenue in the fiscal year 2024 $ 87.68 millions
Y Mabs Therapeutics Inc 's Revenue in the fiscal year 2023 $ 84.82 millions
Y Mabs Therapeutics Inc 's Revenue in the fiscal year 2022 $ 65.27 millions
Y Mabs Therapeutics Inc 's Revenue in the fiscal year 2021 $ 34.90 millions
Y Mabs Therapeutics Inc 's Revenue in the fiscal year 2020 $ 20.75 millions




YMAB Revenue second quarter 2025 Y/Y Growth Comment
Y Mabs Therapeutics Inc reported decline in Revenue in the second quarter 2025 by -17.27% to $ 18.86 millions, from the same quarter in 2024.
The contraction in the second quarter 2025 Y Mabs Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 43.87%.

Looking into second quarter 2025 results within Major Pharmaceutical Preparations industry 86 other companies have achieved higher Revenue growth. While Y Mabs Therapeutics Inc ' s Revenue fall of -17.27% ranks overall at the positon no. 1626 in the second quarter 2025.


YMAB Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 13.4 % -25.72 % 227.6 %
3rd Quarter September - -9.73 % 63.08 % 39.8 %
2nd Quarter June -17.27 % 9.88 % 92.13 % -1.37 %
1st Quarter March 4.87 % -1.58 % 93.04 % 94.98 %
FY   - 3.38 % 29.92 % -

Financial Statements
Y Mabs Therapeutics Inc 's second quarter 2025 Revenue $ 18.86 millions YMAB's Income Statement
Y Mabs Therapeutics Inc 's second quarter 2024 Revenue $ 22.80 millions Quarterly YMAB's Income Statement


YMAB Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 43.5 % 14.23 % 150.8 %
3rd Quarter September - -19.04 % -1.45 % 16.11 %
2nd Quarter June -9.75 % 14.4 % 2.47 % 2.96 %
1st Quarter March -21.1 % -14.68 % -35.61 % 9.27 %
FY (Year on Year)   - 3.38 % 29.92 % -


Back to YMAB Growth rate Comparisons >> Back to YMAB Growth rate Comparisons >>


Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #87
Healthcare Sector #267
Overall #1626

Revenue Y/Y Growth Statistics
High Average Low
113.97 % 43.87 % -5.62 %
(Sep 30 2023)   (Dec 31 2024)
Revenue second quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #87
Healthcare Sector #267
Overall #1626
Revenue Y/Y Growth Statistics
High Average Low
113.97 % 43.87 % -5.62 %
(Sep 30 2023)   (Dec 31 2024)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Y Mabs Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
150.83 % 16.33 % -35.6 %
(Dec 31 2022)  


YMAB's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2025 Y Mabs Therapeutics Inc disclosed drop in Revenue from the first quarter by -9.75% to $ 18.86 millions, from $ 20.90 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2025 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 156 other companies have achieved higher Revenue quarter on quarter growth. While Y Mabs Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2888.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #157
Healthcare Sector #440
Overall #2888
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #157
Healthcare Sector #440
Overall #2888
Revenue Q/Q Growth Statistics
High Average Low
150.83 % 16.33 % -35.6 %
(Dec 31 2022)  


YMAB's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2025 Y Mabs Therapeutics Inc disclosed drop in Revenue from the first quarter by -9.75% to $ 18.86 millions, from $ 20.90 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2025 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 156 other companies have achieved higher Revenue quarter on quarter growth. While Y Mabs Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2888.


Y Mabs Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)
Cumulative Revenue 12 Months Ending $ 84.72 $ 88.66 $ 87.68 $ 84.55 $ 86.55
Y / Y Revenue Growth (TTM) -2.11 % 4.92 % 3.38 % -8.99 % 1.84 %
Year on Year Revenue Growth Overall Ranking # 888 # 372 # 40 # 83 # 88
Seqeuential Revenue Change (TTM) -4.44 % 1.11 % 3.7 % -2.3 % 2.42 %
Seq. Revenue Growth (TTM) Overall Ranking # 1626 # 2439 # 732 # 735 # 562


Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2025 Y Mabs Therapeutics Inc reported a decrease in Revenue by -2.11% year on year, to $85 millions, compare to the 4.92% growth at Mar 31 2025.

In the Healthcare sector 189 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 372 to 888.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 87
Healthcare Sector # 190
Overall # 888

Revenue TTM Y/Y Growth Statistics
High Average Low
113.97 %
 43.87 %
-5.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 267
S&P 500 # 1626
Cumulative Revenue growth Comment
For the 12 months ended Jun 30 2025 Y Mabs Therapeutics Inc reported a decrease in Revenue by -2.11% year on year, to $85 millions, compare to the 4.92% growth at Mar 31 2025.

In the Healthcare sector 189 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 372 to 888.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 87
Healthcare Sector # 190
Overall # 888

Revenue TTM Y/Y Growth Statistics
High Average Low
113.97 %
43.87 %
-5.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 87
Sector # 267
S&P 500 # 1626




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
YMAB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Carlisle Companies Incorporated-0.08%$ -0.076 millions
Zimvie Inc -0.13%$ -0.128 millions
Community Health Systems Inc -0.22%$ -0.223 millions
Bruker Corporation-0.46%$ -0.462 millions
Integra Lifesciences Holdings Corp-0.61%$ -0.615 millions
Adapthealth Corp -0.70%$ -0.695 millions
Perrigo Company Plc-0.79%$ -0.789 millions
Organon and Co -0.81%$ -0.809 millions
Castle Biosciences Inc -0.94%$ -0.936 millions
Vaso Corporation-0.96%$ -0.963 millions
Profound Medical Corp -0.99%$ -0.985 millions
Capsovision Inc -1.13%$ -1.126 millions
Avantor Inc -1.14%$ -1.139 millions
Inspiremd Inc -1.35%$ -1.352 millions
Align Technology inc -1.51%$ -1.509 millions
Teladoc Health Inc -1.64%$ -1.641 millions
Supernus Pharmaceuticals inc -1.71%$ -1.706 millions
Encision Inc -1.73%$ -1.729 millions
Cytek Biosciences Inc -1.80%$ -1.796 millions
Merck and Co Inc -1.90%$ -1.899 millions
Bioventus Inc -1.98%$ -1.978 millions
Alkermes Plc -2.12%$ -2.123 millions
Anteris Technologies Global Corp -2.22%$ -2.215 millions
Surmodics Inc -2.55%$ -2.551 millions
Nrc Health-2.81%$ -2.807 millions
Rxsight Inc -3.09%$ -3.095 millions
Apyx Medical Corp-3.57%$ -3.567 millions
Quidelortho Corp-3.63%$ -3.626 millions
Lantheus Holdings Inc -4.00%$ -4.003 millions
Quipt Home Medical Corp -4.07%$ -4.065 millions


About Y Mabs Therapeutics Inc Revenue Growth Rates (YMAB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Y mabs Therapeutics Inc (CIK 1722964).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001558370-25-010848
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Y mabs Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.